



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

27 June 2019

Imagion Biosystems announces change to Board of Directors

MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the **Company**), a company dedicated to improving healthcare through the earlier detection of cancer, has accepted the resignation of non-executive director Dr. John Hazle, effective today. At this stage the Board does not envisage needing to replace Dr. Hazle with another non-executive director.

Dr. Hazle's involvement with the Company will continue through his appointment as founding Chairman of the Company's Scientific Advisory Board.

Dr. Hazle has been a leading scientific collaborator with the Company for more than five years having established the Magnetic Relaxometry Research Laboratory at the MD Anderson Cancer Center in Houston in 2014. As the Company is now moving closer to clinical testing both the Company and Dr. Hazle believe this change in role is in the best interest of all parties and will eliminate any potential conflicts of interest between his roles at the Company and the MD Anderson Cancer Center, while still allowing Dr. Hazle to continue to be a productive contributor to the success of the Company.

Bob Proulx, Executive Chairman commented, "We are often complemented on the quality of our Board and we've been fortunate to have Dr. Hazle's participation as a non-executive director. Moving forward this change in role will allow us to continue to benefit from his deep expertise and industry connections while still allowing us to work closely with the MD Anderson Cancer Center."

"I continue to be optimistic about Imagion Biosystems and the Company's MagSense technology," stated Dr. Hazle. "I'm looking forward to establishing and leading the Scientific Advisory Board to help guide and fulfill the company's vision of using its technology to achieve early cancer detection and improve cancer care and treatments."

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

Imagion Biosystems Limited

ACN 616 305 027

Level 8, 555 Bourke Street, Melbourne VIC 3000

www.imagionbiosystem.com